Bristol Myers Squibb drug Camzyos has FDA approval for treating obstructive hypertrophic cardiomyopathy, a rare and potentially fatal heart disorder. The drug is projected to become a blockbuster seller and its approval marks a payoff for BMS's 2020 acquisition of the medicine's developer, MyoKardia.
Join Presidio, Cisco Meraki and Purple AI on Thursday, May 5th from 3PM - 4PM EST to learn how you can transform any location into a highly-intelligent smart space.
By Dr. Muthu Alagappan Friday, April 29, 2022 4:37 PM
Offloading menial tasks to digital assistants isn't just about a reduction in workload; it allows physicians to refocus their time on what they entered the profession to do—treating patients.
By Michael Schroeder Friday, April 29, 2022 1:02 PM
Ceryx's device, Cysoni, is designed to pace the heart in rhythm with a person's respiration, so that the heart rate and breathing are synced. This is typically the case for a healthy person, but for someone with heart failure, that link becomes severed, CEO Stuart Plant said.
Bristol Myers Squibb drug Camzyos has FDA approval for treating obstructive hypertrophic cardiomyopathy, a rare and potentially fatal heart disorder. The drug is projected to become a blockbuster seller and its approval marks a payoff for BMS's 2020 acquisition of the medicine's developer, MyoKardia.
In our conversation, Adrienne McFadden, who at one time was a practicing physician, speaks about the evolution of the company to more of a curated matchmaker connecting and guiding people to the best care available. Listen Now!
MedCity News 611 Broadway New York, NY 10012 United States
You received this email because you are subscribed to MedCity Daily Digest from MedCity News.
Update your email preferences to choose the types of emails you receive.
No comments